Lexaria Bioscience Corp (LEXX)

[Shawking]

I'm giving up on Altria and returning to the Remdesivir dream.
We know that Lexaria is starting trials with anti-viral drugs against Covid-19 and that Remdesivir is the leading candidate so it makes sense that Lexy would be trying to formulate an oral version of this drug which is now administered by infusion in hospital. We know that one of the major side effects of Remdesivir is liver toxicity and DehydraTECH claims to avoid first-pass liver metabolism. There is also the possibility of greatly reducing the dosage of Remdesivir being used if DehydraTECH is effective at entering the bloodstream and crossing the Blood/Brain Barrier.
This alone has the potential to send the share price into double digits.
Of course, that's all speculation.